The National Cancer Institute in the USA is supporting the new vaccine developed at the MedUni Vienna against the human papillomavirus (HPV) with at least US$ 3.5 million. This is a major success for the developers and means that the foundations can now be laid for the clinical trials needed for licensing as a vaccine. The National Cancer Institute (NCI) of the US National Institutes of Health (NIH) is supporting further clinical development of a new, improved, next-generation HPV vaccine.
The vaccine was developed by a team led by Reinhard Kirnbauer from the Division of Immunodermatology at the MedUni Vienna in collaboration with Christina Schellenbacher and support from the Austrian Science Fund (FWF) and Vienna Science and Technology Fund (WWTF). The new vaccine had already demonstrated its excellent efficacy in a pre-clinical study in 2013.
READ FULL ARTICLE From Medical Express